Overview

An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women

Status:
Completed
Trial end date:
2015-05-14
Target enrollment:
Participant gender:
Summary
The primary objective of the study was to evaluate the effect of 12 months of treatment with romosozumab compared with teriparatide on total hip bone mineral density (BMD) in postmenopausal women with osteoporosis who were previously treated with bisphosphonate therapy.
Phase:
Phase 3
Details
Lead Sponsor:
Amgen
Treatments:
Teriparatide